Sunitinib Dose Escalation in Metastatic Renal Cell Carcinoma
Background and objective: Sunitinib has been a standard treatment for patients with metastatic renal cell carcinoma (mRCC) since 2006. However, almost all patients will eventually progress. Besides well described mechanisms of primary or secondary resistance, insufficient drug exposure may lead to d...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publishing
2019-08-01
|
| Col·lecció: | Kidney Cancer |
| Accés en línia: | https://doi.org/10.3233/KCA-190055 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|